The Technical Analyst
CEL-SCI Corp [CVM]
Exchange: AMEX Industry: Biotechnology
CEL-SCI Corp Price, Forecast, Insider, Ratings, Fundamentals & Signals
-5.96% $1.420
America/New_York / 10 mai 2024 @ 16:00
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 76.65 mill |
| EPS: | -0.690 |
| P/E: | -2.06 |
| Earnings Date: | May 13, 2024 |
| SharesOutstanding: | 53.98 mill |
| Avg Daily Volume: | 0.360 mill |
| RATING 2024-05-10 |
|---|
| B- |
| Neutral |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Strong Sell | |
| Return On Equity: | Strong Sell | |
| Return On Asset: | Strong Sell | |
| DE: | Strong Buy | |
| P/E: | Sell | |
| Price To Book: | Strong Buy |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
| Revenue | n/a | n/a | n/a | n/a | n/a | n/a |
| Gr.Profit | ||||||
| Ebit | ||||||
| Asset | ||||||
| Debt |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE -2.06 | sector: PE 12.30 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| 0x |
| Company: PE -2.06 | industry: PE -5.55 |
| DISCOUNTED CASH FLOW VALUE |
|---|
|
$-0.212 (-114.92%) $-1.632 |
| Date: 2024-05-12 |
| Expected Trading Range (DAY) |
|---|
|
$ 1.290 - 1.550 ( +/- 9.15%) |
| ATR Model: 14 days |
Insider Trading
| Date | Person | Action | Amount | type |
|---|---|---|---|---|
| 2024-05-08 | Watson Robert Eugene | Buy | 20 000 | Common Stock |
| 2024-05-08 | Prichep Patricia B | Buy | 8 000 | Common Stock |
| 2024-05-08 | Kersten Geert R | Buy | 30 000 | Common Stock |
| 2024-04-19 | Gobbo Mario | Sell | 0 | Common Stock |
| 2024-04-19 | Gobbo Mario | Sell | 64 000 | Options |
| INSIDER POWER |
|---|
| 90.99 |
| Last 100 transactions |
| Buy: 5 675 210 | Sell: 153 000 |
Forecast:
16:00 - $1.420
Live Trading Signals (every 1 min)
Forecast
1: 16:00 - $1.420
Forecast 2: 16:00 - $1.420
Forecast 3: 16:00 - $1.420
SCORE
10.00
Buy
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | $1.420 (-5.96% ) |
| Volume | 0.398 mill |
| Avg. Vol. | 0.360 mill |
| % of Avg. Vol | 110.56 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For CVM
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % |
|---|
CVM
CEL-SCI Corporation engages in the research and development of immunotherapy for the treatment of cancer and infectious diseases. The company's lead investigational immunotherapy is Multikine, which is under phase III clinical trial for the treatment of head and neck cancer. Its Ligand Epitope Antigen Presentation System (LEAPS), a pre-clinical patented T-cell modulation process that stimulates the human immune system to fight bacterial, viral, and parasitic infections, as well as autoimmune diseases, allergies, transplantation rejections, and cancer. The company also develops LEAPS-H1N1-DC; CEL-2000 and CEL-4000 are product candidates for the treatment of rheumatoid arthritis; and LEAPS COV-19, a product candidate to treat COVID-19 coronavirus. CEL-SCI Corporation has a collaboration agreement with the University of Georgia's Center for Vaccines and Immunology to develop LEAPS COVID-19 immunotherapy. The company was incorporated in 1983 and is headquartered in Vienna, Virginia.
Latest Press Releases
2024-05-08 09:00:00 - Press Release
Cel-sci Receives Fda Go-ahead For Its Confirmatory Study Of Multikine In The Treatment Of Head & Neck Cancer
Vienna, va.--(business wire)---- $cvm #multikine--cel-sci receives fda go-ahead for its confirmatory study of multikine in the treatment of head & neck cancer.
2024-04-23 09:00:00 - Press Release
Cel-sci Appoints Mario Gobbo To Its Board Of Directors
Vienna, va.--(business wire)---- $cvm--cel-sci appoints mario gobbo to its board of directors.
2024-04-16 09:00:00 - Press Release
Channel V Media Expands Content Marketing Division; Names Gabriella Bock Director Of Content
New york--(business wire)--channel v media (cvm), a communications strategy and pr firm that builds market momentum for both established enterprises and emerging venture‑backed innovators, today announced the expansion of its 16-year content marketing practice. the company will build on its core competency of creating and executing on lead generation content strategies with the introduction of b2b video and podcasting offerings. leading this expansion will be new director of content, gabriella.
2024-03-19 09:00:00 - Press Release
Cel-sci's Leaps Vaccine Offers Promising New Paradigm To Treat Rheumatoid Arthritis: Published In Frontiers In Immunology
Vienna, va.--(business wire)---- $cvm--cel-sci's leaps vaccine offers promising new paradigm to treat rheumatoid arthritis: published in frontiers in immunology.
2024-03-06 08:45:00 - Press Release
Cel-sci Corporation Issues Letter To Shareholders
Vienna, va.--(business wire)---- $cvm #multikine--cel-sci corporation issues letter to shareholders.
Latest News
2023-07-18 09:00:40 - InvestorPlace
Why Is CEL-SCI (CVM) Stock Down 23% Today?
CEL-SCI (NYSEMKT: CVM ) stock is dropping on Tuesday after the biotechnology company announced details of a public share offering. CEL-SCI is offering up 2.5 million shares of its common stock at a price of $2 per share.
2022-09-30 11:41:40 - Seeking Alpha
CEL-SCI's Multikine - Potential 21st Century Game-Changing Cancer Drug On The Horizon
CEL-SCI demonstrated significant clinical benefits for head & neck cancer patients. In the lower-risk group, there was a 14.1% absolute survival improvement.
2022-04-18 15:05:51 - PennyStocks
3 Penny Stocks to Watch With Above Average Volume Today
Are these high-volume penny stocks on your buy list right now? The post 3 Penny Stocks to Watch With Above Average Volume Today appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
2021-08-11 20:12:40 - Seeking Alpha
CEL-SCI, Poised For Success, Is A Seriously Big Opportunity (Part II)
In our last article, we provided ten reasons why we believe FDA approval of CEL-SCI's drug Multikine and concomitant multibillion dollar valuation is highly likely. This article addresses the critics' main responses, which we believe are logically and factually flawed.
2021-07-14 13:25:03 - Seeking Alpha
CEL-SCI: Pivotal Clinical Trial Results Point To Upside For Patients And Investors
CEL-SCI announced successful Phase III clinical trial results of its drug Multikine, which can treat 155,000 newly diagnosed advanced primary head and neck cancer patients per year globally. Five-year survival: control arm 48.6%, Multikine arm 62.7% (N=380, p=0.0236, HR=0.68); in other words, 21,000 more patients would be alive after five years versus the current standard of care.
2021-07-07 17:20:00 - Pulse2
CEL-SCI Stock Increased 8.5%: Why It Happened
The stock price of CEL-SCI Corporation (NYSEAMERICAN: CVM) increased 8.5%. This is why it happened.
2021-07-07 16:27:43 - The Motley Fool
Why CEL-SCI Stock Soared Today
The company attempted to clarify "confusion" related to its recent late-stage clinical results.
2021-07-05 22:06:00 - Newsfile Corp
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of CEL-SCI Corporation - CVM
New York, New York--(Newsfile Corp. - July 5, 2021) - Pomerantz LLP is investigating claims on behalf of investors of CEL-SCI Corporation ("CEL-SCI" or the "Company") (NYSE American: CVM). Such investors are advised to contact Robert S. Willoughby at newaction@pomlaw.com or 888-476-6529, ext. 7980.The investigation concerns whether CEL-SCI and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. [Click here for information about joining...
2021-07-02 11:20:00 - Business Wire
Discussion of Results of CEL-SCI's Phase 3 Trial Is Now Available
VIENNA, Va.--(BUSINESS WIRE)---- $CVM #HeadandNeckCancer--The discussion of the results of CEL-SCI's Phase 3 Trial is now available.
2021-06-30 12:57:37 - Benzinga
Why CEL-SCI Shares Are Getting Hammered Today
CEL-SCI Corporation (NASDAQ:CVM) shares are trading lower by 27% at $9.33 on continued downward momentum following data from a Phase 3 Study of Multkine showing a 14.1% 5-year survival benefit in groups receiving surgery and radiotherapy for cancer. CEL-SCI is a player in the biotechnology sector.